TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Management of women with postmenopausal bleeding
Key Statistics
- 10–15% — PMB with endometrial cancer
- ≤4 mm — TVS cut-off, sampling not needed
- 96% — Sensitivity, TVS ≤5MM (Smith-Bindman)
Don't-miss facts
-
PMB → 10–15% chance of endometrial cancer; see within 2 weeks; cervical/vulval cancer excluded only by examination
-
ET ≤4 mm on TVS → sampling not needed; post-test probability falls to 1–2.5%
-
Pipelle detects 99.6%, Vabra 97.1% of endometrial carcinomas
-
Hysteroscopy LR+ 62.8, LR– 0.15 for cancer
-
Insufficient sample only safe to reassure if ET ≤4mm and hysteroscopy/TVS = atrophy
-
Tamoxifen → 3–6× endometrial cancer risk (≥4× if >5 years use); PMB is the trigger for investigation, not routine screening
-
Continuous combined HRT bleeding abnormal if after first 6 months or after amenorrhoea established
-
Atypical hyperplasia: RR of carcinoma 14 (95% CI 5–38) → hysterectomy generally recommended
Cut-offs at a glance
ET ≤4mm: no sampling ET >4–5mm: biopsy ± hysteroscopy Asymptomatic: 5.15mm optimal (UKCTOCS)
Abbreviation Key
- PMB — postmenopausal bleeding
- HRT — hormone replacement therapy
- TVS — transvaginal sonography/ultrasound
- EH — endometrial hyperplasia
- SIS — saline infusion sonography
- AH — atypical hyperplasia
- LR — likelihood ratio
- UKCTOCS — UK Collaborative Trial of Ovarian Cancer Screening
- CI — confidence interval
- 3D — three-dimensional
- ROC — receiver operating characteristic
Source: Bakour SH et al. Management of women with postmenopausal bleeding: evidence-based review. The Obstetrician & Gynaecologist 2012;14:243–249. doi:10.1111/j.1744-
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).